Senores Pharmaceuticals Limited (BOM:544319)
India · Delayed Price · Currency is INR 1,042.95
-5.85 (-0.56%)
At close: Jun 4, 2026
Senores Pharmaceuticals Stock Forecast
Stock Price Forecast
According to 4 analysts polled by S&P Global, Senores Pharmaceuticals stock has a consensus rating of "Strong Buy" and an average price target of ₹1,174. The average 1-year stock price forecast is 12.59% higher than the current stock price, while the lowest is ₹972.00 (-6.80%) and the highest is ₹1,310 (+25.61%).
Price Target: ₹1,174 (+12.59%)
Analyst Consensus: Strong Buy
Analyst Ratings
The average analyst rating for Senores Pharmaceuticals stock is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Oct '25 | Nov '25 | Jan '26 | Feb '26 | Apr '26 | May '26 |
|---|---|---|---|---|---|---|
| Strong Buy | 4 | 4 | 4 | 4 | 4 | 4 |
| Buy | 0 | 0 | 0 | 0 | 0 | 0 |
| Hold | 0 | 0 | 0 | 0 | 0 | 0 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 4 | 4 | 4 | 4 | 4 | 4 |
Financial Forecast
Revenue This Year
8.71B
from 6.33B
Increased by 37.75%
Revenue Next Year
11.12B
from 8.71B
Increased by 27.61%
EPS This Year
32.00
from 26.39
Increased by 21.26%
EPS Next Year
43.43
from 32.00
Increased by 35.70%
EPS and Forward PE are based on non-GAAP adjusted numbers. Financial currency is INR.
Revenue Forecast
| Revenue | 2027 | 2028 | 2029 |
|---|---|---|---|
| High | 9.5B | ||
| Avg | 8.7B | ||
| Low | 8.0B |
Revenue Growth
| Revenue Growth | 2027 | 2028 | 2029 |
|---|---|---|---|
| High | 50.4% | ||
| Avg | 37.7% | ||
| Low | 26.0% |
EPS Forecast
| EPS | 2027 | 2028 | 2029 |
|---|---|---|---|
| High | - | ||
| Avg | 32.00 | ||
| Low | - |
EPS Growth
| EPS Growth | 2027 | 2028 | 2029 |
|---|---|---|---|
| High | - | ||
| Avg | 21.3% | ||
| Low | - |